Nu­va­lent nets $200M pub­lic of­fer­ing in wake of pos­i­tive PhI da­ta, paving way for fu­ture tri­als

Af­ter tout­ing some da­ta late last week, Nu­va­lent is at­tempt­ing to cap­i­tal­ize on the mo­men­tum.

The Boston-area biotech an­nounced Mon­day morn­ing it would put to­geth­er …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER